Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
about
Lipids, blood pressure and kidney update 2015Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trialsLipoprotein (a)-We Know So Much Yet Still Have Much to Learn …Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate.Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations.PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Expert opinion: the therapeutic challenges faced by statin intolerance.Evaluating bempedoic acid for the treatment of hyperlipidaemia.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.Management of Statin Intolerance in 2018: Still More Questions Than Answers.Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials.
P2860
Q26771550-FA99BDFE-FC7D-4D53-9688-AC1448F962B8Q28077742-1D319085-D57F-4158-8F31-4B7857A93580Q28275137-9AC51244-EA02-4857-84F1-98A8C5E861FAQ33670893-7E07C117-F4A1-4036-BA97-8B737E2AC682Q33904455-B2BCD4D7-6DDF-483D-B931-3787D73DCDC5Q35232279-0E119D02-0B37-4D35-BCD7-10BE244E6AA2Q35664577-3D532A81-BEBA-4EC8-92FB-920D3A0C56A4Q35894747-BEA1F2C0-E546-4A42-A8A9-1EB47586FD12Q36877240-88B2047C-D110-428B-A053-8E28BFC0F2E3Q37549374-1072AE66-2F42-416C-9C98-051C4C580345Q37636912-808F47DB-72CB-4C63-B59C-B6A49344A686Q38477549-62BE4E6F-9E10-4D1E-BC99-CE7CEB278F48Q38525880-5EE8D218-C2AB-44D0-928D-ABA396345A4BQ38631018-2C42B716-DD73-4CE6-9740-ACE20BB2C419Q38851603-0A505D92-C4FE-4418-8B94-C57BF32C5CC5Q39074339-937E755A-67EF-47AD-BDEA-8C1F247FC353Q40757066-6CFD88E3-C33C-4FD6-AEB6-716AC381A1B8Q48274059-90C8D1B8-53C4-4677-BAB9-4DDD61168813Q53383016-B0A68D3A-8862-418E-B2EC-5BDA701361F0
P2860
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
@en
type
label
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
@en
prefLabel
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
@en
P2860
P356
P1476
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
@en
P2093
Maria-Corina Serban
Simona Dragan
P2860
P304
P356
10.1177/1074248414539562
P577
2014-06-17T00:00:00Z